Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S.P. Treon
PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Ibrutinib Monotherapy Produces Long-Term Disease Control in Previously Treated Waldenstrom's Macroglobulinemia. Final Report of the Pivotal Trial (Nct01614821).
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound
American Journal of Hematology
Hematology
Spotting the Elusive Siberian Tiger: Complete Response to Ibrutinib in a Patient With Waldenström Macroglobulinemia
American Journal of Hematology
Hematology
A Head-To-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients With Waldenström Macroglobulinemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Evauation of Corcordance Between Patient Reported Outcomes (Pros) and Clinician Reported Outcomes (Cros) in Patients With Metastatic Brain Disease
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Rituximab Intolerance in Patients With Waldenström Macroglobulinaemia
British Journal of Haematology
Hematology
Waldenström Macroglobulinemia
Profiling of Circulating Exosomal miRNAs in Patients With Waldenström Macroglobulinemia
PLoS ONE
Multidisciplinary
P3.15-08 Patient-Reported Outcomes (PROs) in Patients With Lung Resection: Open Versus Minimal Invasive Surgery
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
